<DOC>
	<DOCNO>NCT01474421</DOCNO>
	<brief_summary>This study ass safety , tolerability efficacy AQW051 treat moderate severe L-dopa induced dyskinesia ( movement disorder ) patient Parkinson 's disease .</brief_summary>
	<brief_title>Safety Efficacy AQW051 L-dopa Induced Dyskinesias Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients Parkinson 's disease Patients dyskinesias least 3 month Patients moderate severe dyskinesia Patients Ldopa treatment least 3 year Patients atypical Parkinson 's disease Patients prior surgery Parkinson 's disease Patients cognitively impair , psychosis , confusional state hallucinate Patients receive neuroleptic antipsychotic within 2 month Women childbearing potential Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Movement disorder</keyword>
	<keyword>L-dopa</keyword>
</DOC>